If it's in the News, it's in our Polls. Public opinion polling since 2003.

POLITICS

Stem Cell Divide

49% Consider Embryonic Stem Cell Research Morally Acceptable

President George W. Bush’s veto last week of legislation that would increase federal funding for embryonic stem cell research marked another milestone in the ongoing debate over the moral and political implications of this emerging field of research. He was resolute in his decision, but just 26% of American adults believe that embryonic stem cell research is morally wrong. A Rasmussen Reports survey of 1,000 adults taken in the days following the veto reveals that 49% of respondents find the research morally acceptable.

Want to read more?

Become a Rasmussen Reader to read the article

Have an account?

Log In

Become a Reader

Subscribe

Rasmussen Reports is a media company specializing in the collection, publication and distribution of public opinion information.

We conduct public opinion polls on a variety of topics to inform our audience on events in the news and other topics of interest. To ensure editorial control and independence, we pay for the polls ourselves and generate revenue through the sale of subscriptions, sponsorships, and advertising. Nightly polling on politics, business and lifestyle topics provides the content to update the Rasmussen Reports web site many times each day. If it's in the news, it's in our polls. Additionally, the data drives a daily update newsletter and various media outlets across the country.

Some information, including the Rasmussen Reports daily Presidential Tracking Poll and commentaries are available for free to the general public. Subscriptions are available for $4.95 a month or 34.95 a year that provide subscribers with exclusive access to more than 20 stories per week on upcoming elections, consumer confidence, and issues that affect us all. For those who are really into the numbers, Platinum Members can review demographic crosstabs and a full history of our data.

To learn more about our methodology, click here.